Biogen (BIIB) option IV into Clinical Trials on Alzheimer's Congress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) December weekly option implied volatility is at 55, December is at 51; compared to its 52-week range of 29 to 97 into data will be peer reviewed and presented Nov. 29 at the Clinical Trials on Alzheimer's Congress.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $220 at BMO Capital
- Bloom Energy Corp. (BE) call put ratio 1 call to 1.4 puts as share price down 8%
- Toast (TOST) call put ratio 1 call to 1.1 puts
Create E-mail Alert Related Categories
OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
